Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
TRVI Stock | USD 2.82 0.06 2.08% |
Under 66% of Trevi Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that many investors are alarmed at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
Trevi |
Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough , today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant exp
Read at finance.yahoo.com
Trevi Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Trevi Therapeutics Fundamental Analysis
We analyze Trevi Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trevi Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trevi Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Trevi Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Trevi Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Trevi Therapeutics stock to make a market-neutral strategy. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics with similar companies.
Peers
Trevi Therapeutics Related Equities
CUE | Cue Biopharma | 11.93 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
PRLD | Prelude Therapeutics | 7.14 | ||||
BOLT | Bolt Biotherapeutics | 5.00 | ||||
RZLT | Rezolute | 4.18 | ||||
FHTX | Foghorn Therapeutics | 3.59 | ||||
TARA | Protara Therapeutics | 3.40 | ||||
CGEM | Cullinan Oncology | 2.51 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
BCAB | Bioatla | 1.83 | ||||
ORIC | Oric Pharmaceuticals | 1.73 | ||||
SEER | Seer | 1.20 | ||||
ANTX | AN2 Therapeutics | 1.44 | ||||
CHRS | Coherus BioSciences | 1.56 | ||||
SPRO | Spero Therapeutics | 1.74 | ||||
LYRA | Lyra Therapeutics | 5.00 |
Complementary Tools for Trevi Stock analysis
When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |